Creative Medical Technology Holdings Completes The First Phase Of Its Program With Greenstone Biosciences To Develop Next Generation iPSC Pipeline For ImmCelz Immunotherapy Platform
Portfolio Pulse from Benzinga Newsdesk
Creative Medical Technology Holdings (CELZ) has completed the first phase of its program with Greenstone Biosciences to develop a next-generation iPSC pipeline for its ImmCelz immunotherapy platform.
May 31, 2023 | 12:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CELZ has successfully completed the first phase of its program with Greenstone Biosciences, advancing the development of its ImmCelz immunotherapy platform.
The completion of the first phase of the program with Greenstone Biosciences is a positive development for CELZ, as it indicates progress in the development of their ImmCelz immunotherapy platform. This could potentially lead to new treatments and revenue streams for the company, making it a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100